Amgen Inc. (AMGN) EVP Sean E. Harper Sells 1,525 Shares

Amgen Inc. (NASDAQ:AMGN) EVP Sean E. Harper sold 1,525 shares of the business’s stock in a transaction dated Monday, October 9th. The shares were sold at an average price of $185.95, for a total transaction of $283,573.75. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Amgen Inc. (NASDAQ AMGN) opened at 185.79 on Wednesday. The firm’s 50-day moving average is $182.35 and its 200-day moving average is $170.56. The firm has a market cap of $135.57 billion, a price-to-earnings ratio of 16.92 and a beta of 1.36. Amgen Inc. has a 52 week low of $133.64 and a 52 week high of $191.10.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Tuesday, July 25th. The medical research company reported $3.27 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.11 by $0.16. The company had revenue of $5.81 billion during the quarter, compared to the consensus estimate of $5.67 billion. Amgen had a net margin of 35.46% and a return on equity of 29.85%. The firm’s quarterly revenue was up 2.1% on a year-over-year basis. During the same quarter in the previous year, the firm earned $2.84 earnings per share. On average, equities analysts anticipate that Amgen Inc. will post $12.58 earnings per share for the current year.

WARNING: “Amgen Inc. (AMGN) EVP Sean E. Harper Sells 1,525 Shares” was originally published by Markets Daily and is owned by of Markets Daily. If you are viewing this article on another domain, it was illegally copied and republished in violation of U.S. and international trademark and copyright law. The legal version of this article can be viewed at https://www.themarketsdaily.com/2017/10/11/amgen-inc-amgn-evp-sean-e-harper-sells-1525-shares.html.

Several equities research analysts have issued reports on the stock. Royal Bank Of Canada assumed coverage on shares of Amgen in a research report on Thursday, September 14th. They issued a “sector perform” rating and a $192.00 price objective for the company. Bank of America Corporation boosted their price objective on shares of Amgen to $210.00 and gave the company a “buy” rating in a research report on Thursday, October 5th. Oppenheimer Holdings, Inc. reissued a “buy” rating and issued a $203.00 price objective on shares of Amgen in a research report on Friday, October 6th. Morgan Stanley reissued an “overweight” rating and issued a $196.00 price objective (up from $189.00) on shares of Amgen in a research report on Friday, October 6th. Finally, Mizuho reissued a “buy” rating and issued a $198.00 price objective on shares of Amgen in a research report on Friday, October 6th. Ten investment analysts have rated the stock with a hold rating, eleven have given a buy rating and two have issued a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $189.99.

Large investors have recently modified their holdings of the company. TrimTabs Asset Management LLC lifted its position in shares of Amgen by 88.9% during the 1st quarter. TrimTabs Asset Management LLC now owns 612 shares of the medical research company’s stock worth $100,000 after buying an additional 288 shares during the last quarter. Alpha Omega Wealth Management LLC lifted its position in shares of Amgen by 19.0% during the 1st quarter. Alpha Omega Wealth Management LLC now owns 625 shares of the medical research company’s stock worth $103,000 after buying an additional 100 shares during the last quarter. Jackson Grant Investment Advisers Inc. lifted its position in shares of Amgen by 0.6% during the 1st quarter. Jackson Grant Investment Advisers Inc. now owns 636 shares of the medical research company’s stock worth $104,000 after buying an additional 4 shares during the last quarter. Phocas Financial Corp. purchased a new stake in shares of Amgen during the 2nd quarter worth approximately $110,000. Finally, American Beacon Advisors Inc. purchased a new stake in shares of Amgen during the 1st quarter worth approximately $106,000. Institutional investors and hedge funds own 78.10% of the company’s stock.

Amgen Company Profile

Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).

Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply